STAT3是H3K27M突变型弥漫性中线胶质瘤的生物学相关治疗靶点
研究用患者来源的H3K27M突变型弥漫性中线胶质瘤(DMG)细胞系筛选药物,发现STAT3抑制剂在体外有强细胞毒性;pSTAT3(Y705)在突变细胞系和临床标本中选择性上调,STAT3抑制可降低细胞活力并部分恢复H3K27me3表达;WP1066治疗颅内异种移植瘤可使肿瘤生长停滞并延长总生存;pSTAT3(Y705)可在患者血浆细胞外囊泡中检出。
要点
- 激酶抑制剂对H3K27M突变型DMG细胞毒性高,STAT3抑制剂在体外表现出强细胞毒性。
- pSTAT3(Y705)在H3K27M突变型细胞系和临床标本中选择性上调。
- WP1066治疗患者来源颅内异种移植瘤可使肿瘤生长停滞并延长总生存。
核心结论
- STAT3是H3K27M突变型DMG的生物学相关治疗靶点,未来临床试验中应考虑抑制STAT3。
研究设计与样本
- 用FDA已批准或临床试验中的药物库,对患者来源的H3K27M突变型DMG细胞系进行筛选,以细胞活力为结局。
- 结果用活检和尸检患者标本、患者来源细胞系、基因敲低和小分子抑制剂抑制、患者来源异种移植瘤验证临床相关性和机制重要性。
主要发现
- 激酶抑制剂对H3K27M突变型DMG细胞毒性高,STAT3抑制剂在体外表现出强细胞毒性。
- pSTAT3(Y705)在H3K27M突变型细胞系和临床标本中选择性上调。
- CRISPR/Cas9敲除、shRNA或小分子抑制STAT3可降低体外细胞活力,并部分恢复H3K27M突变型DMG中经典丢失的H3K27me3表达。
- 在H3K27M敲除的DMG细胞系中,推测的STAT3调控基因富集,提示K27M突变细胞中STAT3信号相对增加。
- 用WP1066(一种目前用于儿童脑肿瘤临床的STAT3通路抑制剂)治疗患者来源颅内异种移植瘤,导致肿瘤生长停滞并延长总生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: H3K27M-mutant diffuse midline glioma (DMG) is a lethal brain tumor that usually occurs in children. Despite advances in our understanding of its underlying biology, efficacious therapies are severely lacking. METHODS: We screened a library of drugs either FDA-approved or in clinical trial using a library of patient-derived H3K27M-mutant DMG cell lines with cell viability as the outcome. Results were validated for clinical relevance and mechanistic importance using patient specimens from biopsy and autopsy, patient-derived cell lines, inhibition by gene knockdown and small molecule inhibitors, and patient-derived xenografts. RESULTS: Kinase inhibitors were highly toxic to H3K27M-mutant DMG cells. Within this class, STAT3 inhibitors demonstrated robust cytotoxic activity in vitro. Mechanistic analyses revealed one form of activated STAT3, phospho-tyrosine- 705 STAT3 (pSTAT3), was selectively upregulated in H3K27M-mutant cell lines and clinical specimens. STAT3 inhibition by CRISPR/Cas9 knockout, shRNA or small molecule inhibition reduced cell viability in vitro, and partially restored expression of the polycomb repressive mark H3K27me3, which is classically lost in H3K27M-mutant DMG. Putative STAT3-regulated genes were enriched in an H3K27M-knockout DMG cell line, indicating relative gain of STAT3 signaling in K27M-mutant cells. Treatment of patient-derived intracranial xenografts with WP1066, a STAT3 pathway inhibitor currently in clinical use for pediatric brain tumors, resulted in stasis of tumor growth, and increased overall survival. Finally, pSTAT3(Y705) was detected in circulating plasma extracellular vesicles of patients with H3K27M-mutant DMG. CONCLUSIONS: STAT3 is a biologically relevant therapeutic target in H3K27M-mutant DMG. STAT3 inhibition should be considered in future clinical trials.
引用
- Zhang L, Nesvick CL, Day CA, et al. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma. Neuro Oncol. 2022. PMID: 35397475. doi:10.1093/neuonc/noac093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。